XPOVIO® Secures NMPA Approval for Treatment of R/R DLBCL in China, Expanding Its Indications

08 July 2024 | Monday | News

Antengene’s XPOVIO® Gains New Approval as Monotherapy for Relapsed/Refractory Diffuse Large B-cell Lymphoma, Showing Promising Results in the SEARCH Study and Broadening Access Across APAC Markets
Image Source : Public Domain

Image Source : Public Domain

- Following its initial approval for the treatment of relapsed/refractory multiple myeloma (R/R MM), XPOVIO® has now received approval as a monotherapy for the treatment of adult patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) marking the second approved indication of XPOVIO® in China.
- Results from the registrational SEARCH study in China showed that the overall response rate (ORR) among the 60 Chinese patients treated with XPOVIO® met the study's prespecified primary endpoint.
- XPOVIO® is an oral drug with a novel mechanism of action. Antengene is currently developing multiple combination regimens of XPOVIO® for the treatment of various indications including myelofibrosis (MF), T-cell non-Hodgkin's lymphoma (T-NHL), and endometrial cancer.
- XPOVIO® has been approved for health insurance coverage in the mainland of ChinaAustraliaSingapore and South Korea. Furthermore, Antengene has submitted new drug applications (NDAs) for XPOVIO® in other ASEAN markets including ThailandMalaysia and Indonesia. Approvals in these markets are anticipated in the second half of 2024.

Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for cancer, today announced that the China National Medical Products Administration (NMPA) has approved a new indication of XPOVIO® (selinexor) as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL).


A Novel Therapy Bringing Long-awaited Clinical Breakthrough to the Treatment of R/R DLBCL

DLBCL is one of the most common subtypes of non-Hodgkin lymphoma (NHL) in adults and is highly heterogeneous malignancy in both clinical manifestations and prognosis. The current standard treatment, immunotherapy, offers patients with DLBCL a five-year progression-free survival rate of 60%-65% and curative outcomes for 40%-50% of treated patients. However, 10%-15% of DLBCL patients do not respond to standard first-line treatment, and 20%-25% experience relapses after achieving initial responses, leading to a poor prognosis and enormous unmet clinical needs.

The Clinically Validated Efficacy and Convenience of Oral Administration of Selinexor Offer Benefits to a Broad Spectrum of Patients

The approval for the new indication was supported by data from the registrational SEARCH study in China. Results from the study, which enrolled a total of 60 Chinese patients with DLBCL, showed that patients treated in the trial achieved a central radiological review assessed overall response rate (ORR) meeting the pre-specified primary endpoint. The SEARCH study demonstrated clear efficacy of orally-administered selinexor monotherapy in Chinese patients, exhibiting significant response rates, durable responses, long survival. 

Prof. Jun Zhu, principal investigator of the SEARCH study from Peking University affiliated Beijing Cancer Hospital, said, "DLBCL is the most common subtype of NHL in adults and accounts for 40% of all NHL cases in China. The incidence of NHL has been steadily rising year over year, while patients with third- and later-lines relapsed or refractory disease lack effective and convenient therapies. As a nuclear export protein inhibitor with a novel mechanism of action (MOA), selinexor offers patients a new treatment option that is efficacious and easy to use, with oral availability that can reduce hospitalization and financial burden on patients by allowing them to receive treatment at home. Overall, the approval for this new indication of selinexor is indeed a great news for Chinese patients with R/R DLBCL."

Approved in 40+ Markets Globally with Expanding Insurance Coverage Across APAC

With a novel mechanism of action, XPOVIO® is the world's first approved orally-available, selective XPO1 inhibitor. XPOVIO® has a global commercial presence with approvals in over 40 countries and regions. To date, XPOVIO® has already been included for health insurance coverage in the mainland of ChinaAustraliaSingapore and South Korea. Antengene has also submitted the NDAs in additional ASEAN markets, including ThailandMalaysia and Indonesia, where approvals are expected in the H2 of 2024.


Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox


Forgot your password?



Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in